中国现代医学杂志2026，Vol.36Issue(6)：29-33,5.DOI:10.3969/j.issn.1005-8982.2026.06.005
伴高危复发风险肝细胞癌术后辅助治疗的研究进展
Research progress in adjuvant therapy for hepatocellular carcinoma with a high risk of postoperative recurrence
摘要
Abstract
Hepatocellular carcinoma(HCC)is the most common type of primary liver cancer,and surgical resection remains the first-line treatment for patients with resectable disease.However,postoperative recurrence rates of up to 70％severely limit the long-term survival benefits of patients with HCC.Adjuvant therapy after surgery is therefore considered a potential effective strategy to reduce the high risk of recurrence.Accordingly,postoperative adjuvant treatment strategies for patients with HCC at high risk of recurrence have attracted increasing attention in recent years.This review summarizes current studies on adjuvant therapies following curative resection for HCC,including both locoregional and systemic treatments,with the aim of providing a reference for the development of effective adjuvant treatment strategies and future research in patients with a high risk of postoperative recurrence.关键词
肝细胞癌/肝切除术/辅助治疗/复发转移Key words
hepatocellular carcinoma/hepatectomy/adjuvant therapy/recurrence and metastasis分类
医药卫生引用本文复制引用
马金尼,李梓豪,刘福晨,朱秀丽..伴高危复发风险肝细胞癌术后辅助治疗的研究进展[J].中国现代医学杂志,2026,36(6):29-33,5.基金项目
国家自然科学基金青年项目(No:82302906) （No:82302906）
